2025-09-29T11:33:23-05:00 2024-12-31 951777440 GREEN HASSON & JANKS LLP 700 S FLOWER STREET SUITE 3300 LOS ANGELES CA 90017 990 2024-01-01 954418411 PROSTATE CANCER FOUNDATION PROS 3105704700 1250 FOURTH STREET 360 SANTA MONICA CA 904011353 GINA B CARITHERS PRESIDENT & CEO 3105704700 2025-09-25 1 1 LIZBETH G NEVAREZ P01399868 3108731600 2025-09-25 2024 2025-03-06 01:10:19Z GINA B CARITHERS 1250 FOURTH STREET 360 SANTA MONICA CA 904011353 57665336 0 X WWW.PCF.ORG X 1993 CA PCF IS THE LEADING PHILANTHROPIC ORGANIZATION FUNDING HIGH RISK & REWARD PROSTATE CANCER RESEARCH. 33 31 49 31 0 0 54887913 54024868 4555 2687 2398627 2658660 0 0 57291095 56686215 29843227 34297889 0 0 10328164 10350813 14006 13314 3393559 14949366 13515903 55134763 58177919 2156332 -1491704 91770978 105767424 43788553 59314107 47982425 46453317 X THE PROSTATE CANCER FOUNDATION (PCF) FUNDS THE WORLD'S MOST PROMISING RESEARCH ON THE BIOLOGY AND TREATMENT OF PROSTATE CANCER, ACCELERATING THOSE DISCOVERIES INTO THERAPIES AND STRATEGIES DESIGNED TO IMPROVE THE QUALITY OF LIFE AND OVERALL SURVIVAL OF PATIENTS. PCF IS COMMITTED TO THE MISSION OF ENDING DEATH AND SUFFERING FROM THE DISEASE. 0 0 27088259 27088259 THE PCF RESEARCH ENTERPRISE IS A PEER-REVIEW RESEARCH FUNDING PROGRAM THAT PROVIDES FUNDING TO 2,250 SCIENTISTS CONDUCTING INNOVATIVE RESEARCH PROJECTS AT MORE THAN 245 LEADING CANCER CENTERS AND UNIVERSITIES. PRIORITY IS GIVEN TO HIGH-RISK, HIGH-RETURN PROJECTS WITH THE GREATEST POTENTIAL TO IMPROVE SURVIVAL AND THE OVERALL QUALITY OF LIFE FOR MEN WITH PROSTATE CANCER. THE CORNERSTONE OF THE PCF RESEARCH ENTERPRISE IN 2024 WAS OUR CHALLENGE AWARDS PROGRAM AND NEW TACTICAL AWARDS PROGRAM, WHICH SUPPORT CROSS-DISCIPLINARY TEAMS OF INVESTIGATORS CONDUCTING PIONEERING RESEARCH TO ADDRESS CRITICAL UNMET MEDICAL NEEDS FOR PROSTATE CANCER PATIENTS. IN 2024, PCF FUNDED 15 MULTI-YEAR TEAM RESEARCH PROJECTS THAT EACH OFFER HIGH POTENTIAL FOR IMPROVED DETECTION, ENHANCED QUALITY OF LIFE AND HIGHER SURVIVAL RATES. 15750450 2687 FOR MORE THAN 3 MILLION AMERICAN MEN AND THEIR FAMILIES FIGHTING PROSTATE CANCER AND MILLIONS MORE GLOBALLY, PCF SERVES AS A PRIMARY SOURCE FOR NEW STANDARD-OF-CARE AND RESEARCH INFORMATION. PCF EDUCATES THE PUBLIC ABOUT PROSTATE CANCER RISKS, SCREENING, PREVENTION, TREATMENT OPTIONS, AND SIDE EFFECTS. WE CONNECT PATIENTS, LOVED ONES, CARE PROVIDERS, AND SCIENTISTS TO CRITICAL UPDATES, THE LATEST DEVELOPMENTS, BEST PRACTICES, AND NEWS FROM THE TREATMENT PIPELINE. SINCE PCF'S INCEPTION, AND THROUGH ITS EFFORTS, PATIENTS AROUND THE WORLD ARE LIVING LONGER, SUFFERING FEWER COMPLICATIONS, AND ENJOYING BETTER QUALITY OF LIFE. PCF AIMS TO SPUR MEN AND WOMEN ALIKE TO TALK ABOUT THIS DISEASE, TO UNDERSTAND ITS URGENCY, AND TO HAVE INFORMATION-DRIVEN HOPE. 6209630 6209630 PCF CREATED THE YOUNG INVESTIGATOR AWARD PROGRAM WITH ONE GOAL: TO BUILD A GIFTED COHORT OF HUMAN CAPITAL SUPPORTING THE NEXT GENERATION OF PROSTATE CANCER RESEARCHERS. AWARDS ARE MADE TO EARLY-CAREER SCIENTISTS WORKING IN A RESEARCH ENVIRONMENT CAPABLE OF SUPPORTING HIGH-IMPACT PROSTATE CANCER RESEARCH, DRAWN FROM A VARIETY OF MEDICAL RESEARCH DISCIPLINES. IN ITS 27TH YEAR, THE PCF PROGRAM HAS AWARDED NEARLY $93 MILLION TO ADVANCE THE CAREERS OF 435 PCF YOUNG INVESTIGATORS, ENSURING A CONTINUED STREAM OF HUMAN CAPITAL INTO OUR RESEARCH COMMUNITY. THE PCF YOUNG INVESTIGATOR PROGRAM PLAYS AN INTEGRAL ROLE IN CHAMPIONING, MENTORING, AND IDENTIFYING FUTURE MEDICAL RESEARCH PROGRAM LEADERS. 1000000 1000000 MORE THAN 12,000 MEN CARED FOR BY THE DEPARTMENT OF VETERANS AFFAIRS (VA) HOSPITALS ARE NEWLY DIAGNOSED WITH PROSTATE CANCER EACH YEAR, MAKING IT THE MOST FREQUENTLY DIAGNOSED CANCER AMONG VETERANS. THE PCF-VA PARTNERSHIP IS EXPANDING RESEARCH INTO PROSTATE CANCER PRECISION ONCOLOGY TREATMENT OPTIONS. THE COLLABORATION IS EXPANDING THE NUMBER OF PRECISION ONCOLOGY CLINICAL STUDIES CONDUCTED AT VETERANS HEALTH ADMINISTRATION HOSPITALS, ENSURING THAT ELIGIBLE VETERANS CAN ACCESS AND PARTICIPATE IN THESE STUDIES. THE VA'S PRECISION ONCOLOGY PROGRAM FOR CANCER OF THE PROSTATE (POPCAP) WAS ESTABLISHED IN PARTNERSHIP WITH THE PROSTATE CANCER FOUNDATION 2016. THE PROGRAM USES GENETIC TESTING TO FIND THE BEST POSSIBLE TREATMENTS FOR VETERANS WITH ADVANCED PROSTATE CANCER. POPCAP'S NETWORK EXTENDS ACROSS THE U.S. IT INCLUDES 21 PRECISION ONCOLOGY CENTERS OF EXCELLENCE, SUPPLEMENTED BY REGIONAL CENTERS, THAT PROVIDE CANCER CARE TO ANY VETERAN WHO DEVELOPS PROSTATE CANCER, NO MATTER WHERE HE LIVES. 1000000 1000000 50048339 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 92 0 1 49 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 33 31 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT DC FL GA HI IL KS KY MA MD ME MI MN NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV X X HELEN HSIEH 3105704729 1250 4TH ST SUITE 360 SANTA MONICA CA 90401 CHARLES RYAN CEO (DEPARTED 2/2024) 60.00 0.00 X 961414 0 19569 GINA CARITHERS PRESIDENT & CEO 50.00 0.00 X 640810 0 13800 HOWARD SOULE EVP, CHIEF SCIENCE OFFICER 50.00 0.00 X 581029 0 56136 HELEN HSIEH EVP, FINANCE, CAO 50.00 0.00 X 390901 0 55487 JANET HABER VP, EVENTS 50.00 0.00 X 263482 0 22400 CHRISTOPHER CONWAY VP, SPORTS 50.00 0.00 X 243079 0 17761 GEORGE CHONG CONTROLLER 50.00 0.00 X 228630 0 31565 STUART HOLDEN MD DIRECTOR/MEDICAL DIRECTOR 30.00 0.00 X 225000 0 0 ANDREA MIYAHIRA SENIOR DIRECTOR, SCIENCE 50.00 0.00 X 198756 0 49256 ASHLEY HUNTER SENIOR DIRECTOR, MARKETING 50.00 0.00 X 186314 0 42659 WILLIAM OH LEFT 42024 EVP, CHIEF MEDICAL OFFICER 50.00 0.00 X 185984 0 26801 THE REVEREND ROSEY GRIER DIRECTOR 10.00 0.00 X 42000 0 0 MICHAEL MILKEN FOUNDER & CHAIRMAN 15.00 0.00 X X 0 0 0 LORI MILKEN DIRECTOR/VP 2.00 0.00 X X 0 0 0 RALPH FINERMAN CFO, TREASURER, SECRETARY 10.00 0.00 X 0 0 0 KELVIN A BAGGET DIR; SR MANAGING DIR, PATIENT SQUARE CAPITAL 2.00 0.00 X 0 0 0 EMILIO BASSINI DIRECTOR 2.00 0.00 X 0 0 0 PATRICIA BERNS DIRECTOR 2.00 0.00 X 0 0 0 GREGORY BROWN DIRECTOR 2.00 0.00 X 0 0 0 STEVEN A BURD DIRECTOR 2.00 0.00 X 0 0 0 JOSH COHEN DIRECTOR 2.00 0.00 X 0 0 0 NEIL P DEFEO DIRECTOR 2.00 0.00 X 0 0 0 DAVID A EDERER DIRECTOR 2.00 0.00 X 0 0 0 HELMY ELTOUKHY DIRECTOR 2.00 0.00 X 0 0 0 JONATHAN P EVANS DIRECTOR 2.00 0.00 X 0 0 0 R CHRISTIAN B EVENSEN DIRECTOR 2.00 0.00 X 0 0 0 PETER T GRAUER DIRECTOR 2.00 0.00 X 0 0 0 STEIN ERIK HAGEN RETIRED 52024 DIRECTOR 2.00 0.00 X 0 0 0 PHILIP KANTOFF MD DIRECTOR 2.00 0.00 X 0 0 0 FREDA LEWIS-HALL MD DIRECTOR 2.00 0.00 X 0 0 0 THE HONORABLE EARLE I MACK DIRECTOR 2.00 0.00 X 0 0 0 SHMUEL MEITAR DIRECTOR 2.00 0.00 X 0 0 0 MICHAEL MULDOWNEY DIRECTOR 2.00 0.00 X 0 0 0 HENRY L NORDHOFF DIRECTOR 2.00 0.00 X 0 0 0 DAVID DREW PINSKY DIRECTOR 2.00 0.00 X 0 0 0 NEAL I RODIN DIRECTOR 2.00 0.00 X 0 0 0 JASON J SAFRIET DIRECTOR 2.00 0.00 X 0 0 0 RICHARD V SANDLER DIRECTOR 2.00 0.00 X 0 0 0 JONATHAN W SIMONS MD DIRECTOR 2.00 0.00 X 0 0 0 KEITH SHOATES DIRECTOR 2.00 0.00 X 0 0 0 HOWARD SHORE DIRECTOR 2.00 0.00 X 0 0 0 DAVID TAGLIGHT DIRECTOR 2.00 0.00 X 0 0 0 VINCENT J VIOLA DIRECTOR 2.00 0.00 X 0 0 0 KNEELAND YOUNGBLOOD MD DIRECTOR 2.00 0.00 X 0 0 0 JEFF ZISK DIRECTOR 2.00 0.00 X 0 0 0 4147399 0 335434 28 0 1 0 VISION MATRIX PRODUCTIONS INC 5627 KANAN ROAD STE 620 AGOURA HILLS CA 91301 EVENT PRODUCTIONS 1315009 BOULLE EVENT MANAGEMENT 1835 STALLION DR LOXAHATCHEE FL 33470 OUTREACH PROGRAM MGMT 201521 BLUE BRIDGE 20875 NORTH 90TH PLACE STE 210 SCOTTDALE AZ 85255 WEBSITE 171217 MARIA M GELORMINI 27318 SIANDRA CREEK LANE SPRING TX 77383 MANAGEMENT CONSULTANT 164900 CALVIN8 SOLUTIONS LLC 360 STONEBRIDGE DRIVE ROSWELL GA 30075 EVENTS MANAGEMENT 139462 6 2980112 51044756 640153 54024868 EDUCATIONAL MATERIALS 900099 2687 2687 2687 2659864 2659864 701140 702344 -1204 -1204 -1204 276777 2980112 276777 0 56686215 2687 0 2658660 26966735 26966735 7331154 7331154 3198931 2967311 77344 154276 5649915 2559316 2550416 540183 154321 105800 38573 9948 842427 682526 112818 47083 505219 336152 121233 47834 1155343 590221 274904 290218 58952 216 58736 68631 68631 13314 13314 582084 186169 339341 56574 710531 704061 6140 330 1164602 58900 206596 899106 595758 179198 374387 42173 528732 347736 119112 61884 270984 246244 24740 7016356 6153493 13682 849181 101874 101874 505658 445478 45408 14772 128338 67771 60567 MEALS & ENTERTAINMENT 488746 67147 56316 365283 MEMBERSHIP DUES & SUBSC 58404 38183 18821 1400 STORAGE 38988 38988 EDUCATION & TRAINING 20459 1620 18839 21463 12908 8555 58177919 50048339 4736021 3393559 X 372305 791198 50418907 77151270 35951714 23083175 472884 255351 4305228 3966434 480202 338794 701140 0 3302938 3946260 70888 201376 91770978 105767424 2167880 1940407 39330540 54872428 1739373 945624 550760 1555648 43788553 59314107 X 41647013 43763317 6335412 2690000 47982425 46453317 91770978 105767424 X -1491704 -37404 X X 0 1 X 1 0 X 35831174 52997619 71390051 54887913 54024868 269131625 35831174 52997619 71390051 54887913 54024868 269131625 35734972 233396653 36654 14834 526555 2395709 2659864 5633616 274765241 43085 0.84940 0.86550 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 54784360 54784360 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 250000 250000 250000 250000 1000000 1500000 1072625 748576 324049 626025 626025 0 2606578 2591833 14745 338794 OPERATING LEASE LIABILITIES 1555648 1555648 X 56925588 0 56925588 -239373 -239373 56686215 58454696 276777 276777 58177919 0 58177919 PART X, LINE 2: PCF RECOGNIZES THE IMPACT OF TAX POSITIONS IN THE CONSOLIDATED FINANCIAL STATEMENTS IF THAT POSITION IS MORE LIKELY THAN NOT TO BE SUSTAINED ON AUDIT, BASED ON THE TECHNICAL MERITS OF THE POSITION. DURING THE YEAR ENDED DECEMBER 31, 2024, PCF PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS AND DID NOT NOTE ANY MATTERS THAT WOULD REQUIRE RECOGNITION IN THE CONSOLIDATED FINANCIAL STATEMENTS OR WHICH MIGHT HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENTS EXPENSES -276,777. FOREIGN EXCHANGE TRANSLATION 37,404. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENTS EXPENSES 276,777. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 RESEARCH AWARDS CANCER RESEARCH 3098782 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 RESEARCH AWARDS CANCER RESEARCH 3082372 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 RESEARCH AWARDS CANCER RESEARCH 1150000 0 0 0 0 0 0 7331154 0 7331154 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, CANCER RESEARCH 3082372 CHECKS 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 3098782 CHECKS 0 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES CANCER RESEARCH 1150000 CHECKS 0 9 0 0 0 0 0 0 0 PART I, LINE 2: PCF MAKES AWARDS TO FOREIGN INSTITUTIONS WHICH ARE COMPARABLE TO THOSE THAT ARE TRADITIONALLY DEEMED NOT-FOR-PROFIT IN THE UNITED STATES UNIVERSITIES AND THEIR CANCER CENTERS. TO DATE, THE FOREIGN MEDICAL UNIVERSITIES AND RESEARCH INSTITUTES TO WHICH THE FOUNDATION HAS MADE AWARDS HAVE BEEN SUFFICIENTLY RENOWNED IN CANCER RESEARCH PRODUCTIVITY THAT THE FOUNDATION HAS RELIED ON THE GENERAL PUBLIC INFORMATION TO VERIFY THAT THE INSTITUTIONS ARE COMPARABLE TO UNITED STATES NOT-FOR-PROFIT ENTITIES. THE FOUNDATION APPLIES THE SAME NIH PEER REVIEW STANDARDS TO FOREIGN RESEARCH WHICH IT APPLIES TO DOMESTIC RESEARCH. PROGRESS REPORTS FOR EVALUATING RESEARCH PROPOSALS AND SUMMARIES OF FINAL RESULTS ARE REQUIRED AND REVIEWED. IN ADDITION, THE FOUNDATION CONDUCTS SITE VISITS TO EACH FOREIGN INSTITUTION TO REVIEW RESEARCH FUNDING. OTHER THAN VERIFYING THE LEGITIMACY AND CALIBER OF THE INSTITUTIONS' RESEARCH, THESE SITE VISITS ALSO HELP TO IDENTIFY POTENTIAL FUTURE AREAS OF RESEARCH COLLABORATION BETWEEN UNITED STATES AND OUTSTANDING RESEARCH TEAMS AROUND THE WORLD. PALM TENNIS & DINNER 1466889 1355922 110967 109767 1200 HAMPTON TENNIS & DINNERS 1440000 1334644 105356 103564 1792 1 350000 289546 60454 34777 24557 1120 3256889 2980112 276777 34777 237888 4112 276777 0 1 MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10064 131924236 501(C)(3) 4125355 0 CANCER RESEARCH UNIVERSITY OF PENNSYLVANIA 3535 MARKET ST PHILADELPHIA PA 19104 211352685 501(C)(3) 2824975 0 CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 600 N WOLFE ST BALTIMORE MD 21287 520595110 501(C)(3) 2585000 0 CANCER RESEARCH UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746000203 501(C)(3) 2465000 0 CANCER RESEARCH UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DR LA JOLLA CA 92093 656006144 GOVERNMENT 2000000 0 CANCER RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1600 DIVISADERO ST SAN FRANCISCO CA 94143 946036493 GOVERNMENT 1274843 0 CANCER RESEARCH CEDARS SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 501(C)(3) 1225000 0 CANCER RESEARCH UNIVERSITY OF MICHIGAN 530 S STATE ST ANN ARBOR MI 48109 386006309 GOVERNMENT 1167934 0 CANCER RESEARCH DANA-FARBER CANCER INSTITUTE 44 BINNEY ST BOSTON MA 02115 042263040 501(C)(3) 1050000 0 CANCER RESEARCH WEILL CORNELL MEDICAL COLLEGE 575 LEXINGTON DR NEW YORK NY 10065 131623978 501(C)(3) 1032091 0 CANCER RESEARCH UNIVERSITY OF MINNESOTA 420 DELAWARE ST MINNEAPOLIS MN 55455 416007513 GOVERNMENT 1000000 0 CANCER RESEARCH NEW YORK UNIVERSITY 50 WEST 4TH ST NEW YORK NY 10012 135562308 501(C)(3) 1000000 0 CANCER RESEARCH UNIVERSITY OF WISCONSIN 750 HIGHLAND AVE MADISON WI 53705 396006492 501(C)(3) 1000000 0 CANCER RESEARCH UNIVERSITY OF CALIFORNIA LOS ANGELES 405 HILGARD AVE LOS ANGELES CA 90024 956006143 GOVERNMENT 995843 0 CANCER RESEARCH UNIVERSITY OF WASHINGTON 4225 ROOSEVELT WAY NE SEATTLE WA 98105 946036493 501(C)(3) 625000 0 CANCER RESEARCH NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION 4150 CLEMENT ST SAN FRANCISCO CA 94121 943084159 501(C)(3) 500000 0 CANCER RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVE BOSTON MA 02215 042103881 501(C)(3) 450000 0 CANCER RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 1130 ST NICHOLAS AVE NEW YORK NY 10032 135598093 501(C)(3) 225000 0 CANCER RESEARCH UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501(C)(3) 225000 0 CANCER RESEARCH UNIVERSITY OF ROCHESTER 910 GENESEE ST ROCHESTER NY 14611 160743209 GOVERNMENT 225000 0 CANCER RESEARCH UNIVERSITY OF CHICAGO 5801 S ELLIS AVE CHICAGO IL 60637 362177139 501(C)(3) 225000 0 CANCER RESEARCH MASSACHUSETTS GENERAL HOSPITAL 399 REVOLUTION DR STE 645 BOSTON MA 02114 042697983 501(C)(3) 225000 0 CANCER RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK ST EVANSTON IL 60208 362167817 501(C)(3) 225000 0 CANCER RESEARCH FRED HUTCHINSON CANCER RESEARCH INSTITUTE PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 214694 0 CANCER RESEARCH NATIONAL ASSOCIATION OF VETERANS RESEARCH AND EDUCATION 177 K STREET NW WASHINGTON DC 20006 521784596 501(C)(3) 50000 0 CANCER RESEARCH JOE TORRE SAFE AT HOME 55 WEST 39TH ST NEW YORK NY 10018 030442514 501(C)(3) 25000 0 PUBLIC AWARENESS AMERICAN ASSOCIATION OF CANCER RESEARCH 615 CHESTNUT STREET 17TH FLOOR PHILADELPHIA PA 19106 236251648 501(C)(3) 6000 0 PUBLIC AWARENESS 27 PART I, LINE 2: THE PROSTATE CANCER FOUNDATION (PCF) MONITORS THE PROGRESS OF RESEARCH THROUGH SCHEDULED SITE VISITS BY THE CHIEF SCIENCE OFFICER AND CEO AND WRITTEN PROGRESS REPORTS SUBMITTED BY THE RESEARCH INSTITUTIONS. EVERY FUNDED PCF INVESTIGATOR PARTICIPATES IN POWER POINT FORMATTED VIDEO CONFERENCES SHARING UNPUBLISHED DATA AND DATA SUBMITTED FOR PUBLICATIONS. THE PROSTATE CANCER FOUNDATION (PCF) HAS A TRANSPARENT AND COMPETITIVE PROCESS FOR SELECTION OF RESEARCH AWARDS. A REQUEST FOR APPLICATIONS (RFA) IS EMAILED TO POTENTIAL APPLICANTS AROUND THE WORLD AND POSTED PUBLICLY ON THE PCF WEBSITE. THE RFA LISTS THE AWARD EXPECTATIONS, DETAILED INSTRUCTIONS AND DEADLINE. COMPLETE APPLICATIONS ARE SUBMITTED ELECTRONICALLY TO PCF. EACH APPLICATION IS SENT TO 2 OR MORE SCIENTIFIC EXPERTS FOR PEER REVIEW. THE FOUNDATION EMPLOYS ALL THE PRINCIPLES AND PRACTICES OF NIH PEER REVIEWS. THE REVIEWERS ASSIGN SCORES TO THE APPLICATIONS AND ADHERE TO STRICT CONFIDENTIALITY AND CONFLICT OF INTEREST POLICIES. THE FINAL SCORES ALLOW PCF TO RANK THE APPLICATIONS FOR PRIORITY OF FUNDING. THE RANKED PROPOSALS ARE THEN PRESENTED TO AN EXPERT PANEL OF PROSTATE CANCER RESEARCHERS FOR FINAL VOTING IN A JURY FORMAT WITH SELECTION FOR FUNDING. ALL FUNDING RECOMMENDATIONS ARE SUBJECT TO THE APPROVAL OF PCF BOARD OF DIRECTORS' DISCOVERY AND TRANSLATION COMMITTEE. X X X X X 1 0 0 0 0 0 0 1 1 0 CHARLES RYAN CEO (DEPARTED 2/2024) 61414 0 0 0 900000 0 5000 0 14569 0 980983 0 0 0 GINA CARITHERS PRESIDENT & CEO 640810 0 0 0 0 0 13800 0 0 0 654610 0 0 0 HOWARD SOULE EVP, CHIEF SCIENCE OFFICER 556029 0 25000 0 0 0 13800 0 42336 0 637165 0 0 0 HELEN HSIEH EVP, FINANCE, CAO 370901 0 20000 0 0 0 13800 0 41687 0 446388 0 0 0 JANET HABER VP, EVENTS 238482 0 25000 0 0 0 0 0 22400 0 285882 0 0 0 CHRISTOPHER CONWAY VP, SPORTS 243079 0 0 0 0 0 9745 0 8016 0 260840 0 0 0 GEORGE CHONG CONTROLLER 218630 0 10000 0 0 0 9165 0 22400 0 260195 0 0 0 STUART HOLDEN MD DIRECTOR/MEDICAL DIRECTOR 0 0 0 0 225000 0 0 0 0 0 225000 0 0 0 ANDREA MIYAHIRA SENIOR DIRECTOR, SCIENCE 188756 0 10000 0 0 0 8342 0 40914 0 248012 0 0 0 ASHLEY HUNTER SENIOR DIRECTOR, MARKETING 176314 0 10000 0 0 0 7687 0 34972 0 228973 0 0 0 WILLIAM OH LEFT 42024 EVP, CHIEF MEDICAL OFFICER 185984 0 0 0 0 0 7603 0 19198 0 212785 0 0 0 PART I, LINE 4A CHARLES RYAN RECEIVED SEVERANCE PAYMENT OF $900,000. PART I, LINE 7 THE COMMITTEE AWARDED THE DISCRETIONARY BONUSES TO THE OFFICERS AND EMPLOYEES BASED ON EXCEPTIONAL INDIVIDUAL PERFORMANCE. X 26 640153 MARKET PRICE 0 0 0 PART I, COLUMN (B): THE PUBLICLY TRADED SECURITIES ARE VALUED USING THE MEAN PRICE ON THE DAY OF RECEIPT. LETTERS LISTING GOODS AND SERVICES, IF ANY, ARE MAILED TO THE DONORS. NONCASH CONTRIBUTIONS ARE LISTED BY NUMBER OF CONTRIBUTORS. FORM 990, PART VI, SECTION A, LINE 2 MICHAEL MILKEN (CHAIRMAN) FAMILY AND BUSINESS RELATIONSHIP; LORI MILKEN (DIRECTOR/VP) FAMILY AND BUSINESS RELATIONSHIPS; RALPH FINERMAN (TREASURER/CFO) BUSINESS RELATIONSHIP; RICHARD SANDLER (DIRECTOR) BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS REVIEWED BY THE FOUNDATION'S CEO, PRESIDENT, CFO AND EXECUTIVE VP FINANCE AND ADMINISTRATION BEFORE DISTRIBUTION TO THE AUDIT COMMITTEE FOR REVIEW AND FINAL APPROVAL. THE ENTIRE BOARD RECEIVES A COPY OF FORM 990 AND HAS AN OPPORTUNITY TO RAISE ISSUES PRIOR TO BEING FILED. FORM 990, PART VI, SECTION B, LINE 12C THE FOUNDATION'S BOARD OF DIRECTORS ADOPTED A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS AND OFFICERS CONSISTENT WITH THE MODEL SUGGESTED BY THE INTERNAL REVENUE SERVICE. THE POLICY REQUIRES THAT DIRECTORS AND OFFICERS DISCLOSE ANY TRANSACTIONS IN WHICH THEY HAVE A FINANCIAL INTEREST TO THE FOUNDATION'S GENERAL COUNSEL. THE GENERAL COUNSEL IS RESPONSIBLE FOR GATHERING INFORMATION AND PREPARING A REPORT REGARDING ANY PROPOSED TRANSACTION WHERE THERE IS A DISCLOSED FINANCIAL INTEREST AND DETERMINING WHETHER OR NOT THE TRANSACTION REASONABLY COULD BE DETERMINED TO MEET THE FOUNDATION'S STANDARDS FOR APPROVING A TRANSACTION, IN WHICH AN OFFICER OR DIRECTOR HAS A FINANCIAL INTEREST (I.E., THE BEST INTERESTS OF THE FOUNDATION FOR THE FOUNDATION'S BENEFIT AND FAIR AND REASONABLE AS TO THE FOUNDATION). IF PCF'S GENERAL COUNSEL DETERMINES THE TRANSACTION MAY MEET THE APPROVAL STANDARD, THE TRANSACTION IS REVIEWED BY AND EITHER APPROVED OR DISAPPROVED BY A COMMITTEE OF THE BOARD OF DIRECTORS OR THE ENTIRE BOARD OF DIRECTORS CONSISTENT WITH APPLICABLE STATE CORPORATE LAW REQUIREMENTS. AS PART OF THE REVIEW PROCESS, COMMITTEE OF BOARD OF DIRECTORS IS REQUIRED TO IDENTIFY AND EVALUATE POTENTIAL ALTERNATIVE TRANSACTIONS WHICH DO NOT INVOLVE A FOUNDATION OFFICER OR DIRECTOR. THE INTERESTED OFFICER OR DIRECTOR IS ALLOWED TO PRESENT INFORMATION TO THE COMMITTEE OR BOARD OF DIRECTORS BUT MUST LEAVE THE MEETING AT WHICH THE TRANSACTION IS CONSIDERED PRIOR TO THE FINAL VOTE. THE FOUNDATION'S CONFLICT OF INTEREST POLICY ALSO REQUIRES OFFICERS AND DIRECTORS TO COMPLETE ANNUAL QUESTIONNAIRES WHEREIN THEY ARE ASKED TO IDENTIFY ALL TRANSACTIONS WHERE THEY MAY HAVE AN ACTUAL OR PERCEIVED CONFLICT OF INTEREST. AS PART OF THE QUESTIONNAIRE, EACH OFFICER AND DIRECTOR IS REQUIRED TO CONFIRM THEIR UNDERSTANDING THAT THE FOUNDATION IS A TAX EXEMPT ENTITY AND MUST ENGAGE PRIMARILY IN ACTIVITIES WHICH FURTHER ITS MISSION.THE FOUNDATION'S SCIENTIFIC REVIEW PANELS DETERMINE WHICH RESEARCH PROJECTS OR TYPES OF PROJECTS WILL BE FUNDED BY THE FOUNDATION, AND ALSO HAS A CONFLICT OF INTEREST POLICY. PANELISTS ARE REQUIRED TO ABSTAIN FROM DISCUSSIONS AND VOTES REGARDING FUNDING FOR RESEARCH PROJECTS IN WHICH THEY HAVE A FINANCIAL OR PROFESSIONAL INTEREST OR INSTITUTIONAL AFFILIATION. FORM 990, PART VI, SECTION B, LINE 15 STAFF COMPENSATION, INCLUDING OFFICERS AND KEY EMPLOYEES, LISTED ON SCHEDULE J ARE REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS' COMPENSATION COMMITTEE BASED ON QUALIFICATIONS AND MARKET COMPARABILITY IN SIMILAR INDUSTRIES. THE LAST COMPENSATION REVIEW OCCURRED IN DECEMBER 2022. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION POSTS ITS ANNUAL REPORT, AUDITED FINANCIAL STATEMENTS AND FORM 990 ON ITS WEBSITE WWW.PCF.ORG (GO TO "ABOUT PCF/WHERE YOUR MONEY GOES"). THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE ALSO POSTED ON THE WEBSITE WWW.PCF.ORG. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE TRANSLATION -37,404. FORM 990, PART XII, LINE 2C: NO PROCESSES HAVE CHANGED FROM THE PRIOR YEAR. DIGITAL SCIENCE PRESS LLC 1390 IONE PRASS TRAIL RENO NV 89523 873985005 MEDICAL EDUCATION NV 3988122 4690817 PROSTATE CANCER FOUNDATION